Heron Therapeutics, Inc. (HRTX) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) from a sell rating to a hold rating in a report published on Wednesday morning.

According to Zacks, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. “

HRTX has been the topic of several other reports. Noble Financial reissued a buy rating and issued a $24.00 price objective on shares of Heron Therapeutics in a research report on Friday, October 6th. Cantor Fitzgerald reissued a buy rating on shares of Heron Therapeutics in a research report on Monday, September 25th. Oppenheimer Holdings, Inc. started coverage on shares of Heron Therapeutics in a research report on Monday, October 30th. They issued a buy rating and a $27.00 price objective on the stock. Cowen and Company reissued a buy rating and issued a $40.00 price objective on shares of Heron Therapeutics in a research report on Monday, November 6th. Finally, Mizuho reissued a buy rating and issued a $28.00 price objective on shares of Heron Therapeutics in a research report on Tuesday, November 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $28.36.

Heron Therapeutics (NASDAQ:HRTX) opened at $16.35 on Wednesday. Heron Therapeutics has a 1 year low of $12.21 and a 1 year high of $20.85. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.72 and a current ratio of 2.12.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.10. The company had revenue of $8.57 million for the quarter, compared to analyst estimates of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. equities analysts expect that Heron Therapeutics will post -3.42 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://sportsperspectives.com/2017/11/12/heron-therapeutics-inc-hrtx-stock-rating-upgraded-by-zacks-investment-research.html.

Large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc increased its position in Heron Therapeutics by 13.9% during the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 1,098 shares during the period. Quantbot Technologies LP increased its position in Heron Therapeutics by 2,619.6% during the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock worth $172,000 after acquiring an additional 12,024 shares during the period. Trexquant Investment LP acquired a new stake in Heron Therapeutics during the third quarter worth about $206,000. HighTower Advisors LLC grew its stake in Heron Therapeutics by 11.4% during the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after buying an additional 1,700 shares in the last quarter. Finally, Tudor Investment Corp ET AL acquired a new stake in Heron Therapeutics during the first quarter worth about $253,000.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply